Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an autoimmune disorder that causes progressive weakness and sensory loss in the arms and legs. It is the chronic counterpart of Guillain-Barré syndrome and is characterized by demyelination of peripheral nerves. [1] CIDP represents the most common chronic autoimmune neuropathy, with an estimated prevalence of 1-9 per 100,000 individuals worldwide. The disease typically presents in adults between the ages of 40-60, though it can occur at any age, including in children and the elderly. [@KuKu2022]
The pathophysiology of CIDP involves a dysregulated immune response targeting peripheral nerve myelin. Both cellular and humoral immune mechanisms contribute to disease pathogenesis, with T-cell activation, macrophage-mediated demyelination, and antibody-mediated complement activation all playing roles. [2] This immune attack results in segmental demyelination, onion bulb formation (characteristic concentric layers of Schwann cell processes), and varying degrees of axonal loss, which together produce the clinical manifestations of progressive motor and sensory deficits.
CIDP has an estimated annual incidence of 1-2 per 100,000 population, with a prevalence ranging from 1.6 to 10.3 per 100,000 depending on geographic region and diagnostic criteria used. [1:1] The disease affects both genders, with a slight male predominance (approximately 1.3:1 male-to-female ratio). Peak incidence occurs in the fifth and sixth decades of life, though childhood onset accounts for approximately 10-15% of cases.
Several risk factors have been implicated in CIDP susceptibility, including:
CIDP typically presents with a subacute onset over weeks to months of progressive symmetric motor and sensory symptoms. The clinical phenotype can vary significantly between patients, leading to recognition of distinct clinical variants. [4]
Motor symptoms include:
Sensory symptoms include:
Several distinct clinical variants of CIDP have been recognized: [4:1]
| Variant | Characteristics |
|---|---|
| Typical CIDP | Classic presentation with progressive, symmetric, proximal and distal weakness with sensory involvement |
| Pure sensory CIDP | Predominantly sensory symptoms with minimal or no motor involvement |
| Pure motor CIDP | Prominent motor weakness without significant sensory deficits |
| Focal/Multifocal (MADSAM) | Asymmetric or multifocal presentation, also known as Lewis-Sumner syndrome |
| Distal acquired demyelinating symmetric (DADS) | Predominantly distal weakness and sensory loss |
| Pediatric CIDP | Presents in children with often more prominent sensory features |
Physical examination typically reveals:
CIDP is characterized by immune-mediated damage to the myelin sheath of peripheral nerves. The exact trigger is unknown, but it is thought to involve both cellular and humoral immune responses. T-cells, macrophages, and antibodies target myelin proteins and lipids, leading to demyelination and subsequent nerve conduction deficits. In some cases, CIDP may be associated with other conditions such as diabetes, HIV, or monoclonal gammopathy. [2:1]
The cellular immune response in CIDP involves both CD4+ and CD8+ T-cells:
Antibody-mediated mechanisms play a significant role in CIDP pathogenesis:
Nerve biopsy findings in CIDP include:
Diagnosis is based on clinical presentation, nerve conduction studies showing demyelination, and cerebrospinal fluid analysis (elevated protein with normal cell count). Nerve biopsy may be performed in atypical cases. [@KuKu2022]
The EFNS/PNS guidelines establish diagnostic criteria requiring:
Nerve conduction studies (NCS) and electromyography (EMG) are essential for diagnosis:
Cerebrospinal fluid (CSF) analysis typically shows:
Nerve ultrasound and MRI can provide supportive evidence:
Recent research has identified potential biomarkers: [5] [6]
CIDP must be distinguished from other demyelinating neuropathies including:
First-line treatments for CIDP include corticosteroids (such as prednisone), intravenous immunoglobulin (IVIG), and plasma exchange (plasmapheresis). These treatments aim to suppress the immune system's attack on the myelin sheath. IVIG is often preferred due to its rapid onset of action and favorable side effect profile. Immunosuppressive agents may be considered for patients who do not respond to first-line therapies. [7]
| Treatment | Mechanism | Administration | Efficacy |
|---|---|---|---|
| IVIG | Immunomodulation via Fc receptor blockade, complement inhibition | 2 g/kg over 2-5 days, repeat as needed | 60-80% response rate |
| Plasma exchange | Removal of pathogenic antibodies | 4-6 exchanges over 2-3 weeks | 70-80% response rate |
| Corticosteroids | Broad immunosuppression | Prednisone 1 mg/kg/day, taper over months | 60-70% response rate |
Oral corticosteroids (prednisone, prednisolone) or intravenous methylprednisolone are commonly used: [8]
IVIG is often preferred due to its rapid onset of action and favorable side effect profile: [9]
Plasma exchange (PLEX) is particularly useful for severe or rapidly progressive disease: [10]
For patients refractory to first-line treatments: [11]
| Agent | Mechanism | Typical Response |
|---|---|---|
| Azathioprine | Purine analog, T-cell suppression | 30-40% after 3-6 months |
| Methotrexate | Folate antagonist, lymphocyte inhibition | 30-40% after 3-6 months |
| Cyclosporine | Calcineurin inhibitor | 40-50% response |
| Mycophenolate mofetil | IMP dehydrogenase inhibitor | 40-50% response |
| Cyclophosphamide | Alkylating agent | 50-60% response |
| Rituximab | Anti-CD20, B-cell depletion | Variable, particularly in autoantibody-positive |
Recent therapeutic developments include: [12] [13]
The prognosis for CIDP varies significantly among patients. Some individuals experience a monophasic course with complete recovery, while others have a relapsing-remitting or progressive pattern. Early diagnosis and treatment are associated with better outcomes. Long-term follow-up is essential to monitor for treatment response and adjust therapy as needed. [10:1]
Approximately one-third of CIDP patients follow each of these patterns: [14]
Favorable prognosis:
Poor prognosis:
Long-term studies show:
Current research focuses on identifying biomarkers for treatment response, understanding the underlying autoimmune mechanisms, and developing more targeted therapies. Clinical trials are investigating novel immunosuppressive agents, stem cell therapy, and gene therapy approaches for CIDP. [11:1]
Multiple Phase 2 and Phase 3 trials are ongoing, investigating:
While CIDP is primarily an autoimmune neuropathy, it intersects with neurodegenerative disease research in several important ways:
Techniques developed for CIDP research have applications in neurodegeneration:
van Doorn et al. "Chronic inflammatory demyelinating polyradiculoneuropathy" (2017). 2017. ↩︎ ↩︎
Kline et al. "CIDP pathophysiology and biomarkers" (2016). 2016. ↩︎ ↩︎
Session et al. "Genetics of CIDP susceptibility" (2023). 2023. ↩︎
Burns et al. "CIDP subtypes and classification" (2018). 2018. ↩︎ ↩︎
Kline et al. "Neurofilament light chain as CIDP biomarker" (2019). 2019. ↩︎
van Lieburg et al. "NF-L in CIDP disease activity" (2023). 2023. ↩︎
Rajabally et al. "Guidelines on management of CIDP" (2021). 2021. ↩︎
Sander et al. "Corticosteroids in CIDP treatment" (2021). 2021. ↩︎
Guptarak et al. "IVIG treatment mechanisms in CIDP" (2012). 2012. ↩︎
Bunschoten et al. "Clinical outcomes in CIDP" (2021). 2021. ↩︎ ↩︎
Lehmann et al. "Novel therapies for refractory CIDP" (2023). 2023. ↩︎ ↩︎
Cornelius et al. "Efgartigimod in CIDP Phase 2 trial" (2023). 2023. ↩︎
van Schaik et al. "Ravulizumab in CIDP" (2024). 2024. ↩︎
Mathey et al. "CIDP chronic progression and treatment response" (2015). 2015. ↩︎